Table 1. Baseline and demographic characteristics of patients				
Characteristics	**Total (n=62)**	**First line (n=33)**	**Second line (n=26)**	**Third line (n=3)**
Age (years)				
• **Median**	64	64	64	69
• **Rank**	39-86	40-75	39-86	55-78
• **Age (category) - n (%)**				
< 65 years	33 (53.23%)	18 (54.55%)	12 (46.15%)	1 (33.33%)
≥ 65-75	22 (35.48%)	11 (33.33%)	10 (38.46%)	1 (33.33%)
≥ 75	7 (11.29%)	2 (6.06%)	4 (15.38%)	1 (33.33%)
Sex - n (%)				
Men	48 (77.42%)	26 (78.79%)	19 (73.08%)	3 (100%)
Women	14 (22.58%)	7 (21.21%)	7 (26.92%)	0
ECOG - n (%)				
0	19 (30.65%)	10 (30.30%)	8 (30.77%)	1 (33.33%)
1	37 (59.68%)	19 (57.58%)	16 (61.54%)	2 (66.67%)
≥2	4 (6.45%)	3 (9.09%)	1 (3.85%)	-
Not collected	2 (3.23%)	1 (3.03%)	1 (3.85%)	-
CNS†Metastases - n (%)	16 (25.81%)	11 (33.33%)	4 (15.38%)	1 (33.33%)
Previous treatment - n (%)				
Carboplatin-gemcitabine	10 (16.13%)	-	9 (34.62%)	1 (33.33%)
Carboplatin-taxol	8 (12.90%)	-	7 (26.92%)	1 (33.33%)
Carboplatin-pemetrexed	11 (17.74%)	-	10 (38.46%)	1 (33.33%)
Cisplatin-vinorelbine	2 (3.23%)	-		2 (66.67%)
Tumour Histological features - n (%)				
Squamous	25 (40.32%)	13 (39.39%)	11	1 (33.33%)
Non-squamous	35 (56.45%)	20 (60.61%)	13 (50%)	2 (66.67%)
Unknown	2 (3.23%)	-	2 (7.69%)	-
Smoking status - n (%)				
Smokers	55 (88.71%)	29 (87.88%)	23 (88.46%)	3 (100%)
Non-smokers	7 (11.29%)	4 (12.12%)	3 (11.54%)	-
PD-L1 level (%)- n (%)				
(≥50%)	52 (83.87%)	31 (9.94%)	19 (73.08%)	2 (66.67%)

20-49	1 (1.61%)	-	1 (3.85%)	-
1-19	9 (14.52%)	2 (6.06%)	6 (23.08%)	1 (33.33%)

Table 2. Adverse events of any grade in the study population* - n (%)

Adverse event	n (%)
Asthenia	28 (45.16%)
Arthralgia	8 (12.90%)
Hypothyrodism	6 (9.67%)
Diarrhoea-colitis	5 (8.06%)
Hyporexia	4 (6.45%)
Pruritus	4 (6.45%)
Nausea	4 (6.45%)
Pneumonitis	3 (4.83%)
Constipation	3 (4.83%)
Vomit	3 (4.83%)
Anorexy	2 (3.22%)
Respiratory tract infection	2 (3.22%)
Myalgia	2 (3.22%)
Liver toxicity	2 (3.22%)
Hyperuicemia	2 (3.22%)
Renal toxicity	1 (1.61%)
Thrombopenia	1 (1.61%)
Anaemia	1 (1.61%)
Neutropenia	1 (1.61%)
Hyperthyroidism	1 (1.61%)
Hypercholesterolemia	1 (1.61%)
Hypertriglyceridemia	1 (1.61%)
Episcleritis	1 (1.61%)
Skin rash	1 (1.61%)

*Adverse events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0.

Table 3. Adverse events G3* - n (%)

Adverse Event G3	n (%)
Colitis	3 (4.83%)
Asthenia	2 (3.22%)
Nephritis	2 (3.22%)
Hyporexia	1 (1.61%)
Anaemia	1 (1.61%)

*Adverse events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0.